Fabio Luis Monteiro

Fabio Luis Monteiro

Auto-generated profile, based on publicly available information

Fabio Luis Monteiro

Department of Genetics, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
IMIara J.F. Motta
Iara J.F. Motta
BSBryan R. Spencer
Bryan R. Spencer
SSSuely G. Cordeiro da Silva
Suely G. Cordeiro da Silva
MAMonica B. Arruda
Monica B. Arruda
JDJane A. Dobbin
Jane A. Dobbin
OFOrlando C. Jr. Ferreira
Orlando C. Jr. Ferreira
Zika virus (ZIKV) is a mosquito-borne virus that has important secondary means of transmission that include perinatal and sexual modes.1-3 The potential for transmission in transfused donated blood components has been a concern owing to the detection of ZIKV viremia in healthy blood donors.4

29 November 2016 in Viruses
Verified
Journal Article
Open access
PDF file
RDRodrigo Delvecchio
Rodrigo Delvecchio
LHLuiza Higa
Luiza Higa
PPPaula Pezzuto
Paula Pezzuto
AVAna Luiza Valadão
Ana Luiza Valadão
PGPatricia Pestana Garcez
Patricia Pestana Garcez
ATAmilcar Tanuri
Amilcar Tanuri
Zika virus (ZIKV) infection in utero might lead to microcephaly and other congenital defects. Since no specific therapy is available thus far, there is an urgent need for the discovery of agents capable of inhibiting its viral replication and deleterious effects. Chloroquine is widely used as an antimalarial drug, anti-inflammatory agent, and it also shows antiviral activity against several viruses. Here we show that chloroquine exhibits antiviral activity against ZIKV in Vero cells, human brain microvascular endothelial cells, human neural stem cells, and mouse neurospheres. We demonstrate that chloroquine reduces the number of ZIKV-infected cells in vitro, and inhibits virus production and cell death promoted by ZIKV infection without cytotoxic effects. In addition, chloroquine treatment partially reveres morphological changes induced by ZIKV infection in mouse neurospheres.

30 January 2019 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
Caroline De FreitasCaroline De Freitas
Caroline De Freitas
LHLuiza M Higa
Luiza M Higa
CSCarolina Q Sacramento
Carolina Q Sacramento
AFAndré C Ferreira
André C Ferreira
PRPatrícia A Reis
Patrícia A Reis
TSThiago Moreno Lopes e Souza
Thiago Moreno Lopes e Souza
Yellow fever virus (YFV) is a member of the Flaviviridae family. In Brazil, yellow fever (YF) cases have increased dramatically in sylvatic areas neighboring urban zones in the last few years. Because of the high lethality rates associated with infection and absence of any antiviral treatments, it is essential to identify therapeutic options to respond to YFV outbreaks. Repurposing of clinically approved drugs represents the fastest alternative to discover antivirals for public health emergencies. Other Flaviviruses, such as Zika (ZIKV) and dengue (DENV) viruses, are susceptible to sofosbuvir, a clinically approved drug against hepatitis C virus (HCV). Our data showed that sofosbuvir docks onto YFV RNA polymerase using conserved amino acid residues for nucleotide binding. This drug inhibited the replication of both vaccine and wild-type strains of YFV on human hepatoma cells, with EC50 values around 5 μM. Sofosbuvir protected YFV-infected neonatal Swiss mice and adult type I interferon receptor knockout mice (A129-/-) from mortality and weight loss. Because of its safety profile in humans and significant antiviral effects in vitro and in mice, Sofosbuvir may represent a novel therapeutic option for the treatment of YF. Key-words: Yellow fever virus; Yellow fever, antiviral; sofosbuvir Yellow fever virus is transmitted by mosquitoes and its infection may be asymptomatic or lead to a wide clinical spectrum ranging from a mild febrile illness to a potentially lethal viral hemorrhagic fever characterized by liver damage. Although a yellow fever vaccine is available, low coverage allows 80,000–200,000 cases and 30,000–60,000 deaths annually worldwide. There are no specific therapy and treatment relies on supportive care, reinforcing an urgent need for antiviral repourposing. Here, we showed that sofosbuvir, clinically approved against hepatitis C, inhibits yellow fever virus replication in liver cell lines and animal models. In vitro, sofosbuvir inhibits viral RNA replication, decreases the number of infected cells and the production of infectious virus particles. These data is particularly relevante since the liver is the main target of yellow fever infection. Sofosbuvir also protected infected animals from mortality, weight loss and liver injury, especially prophylatically. Our pre-clinical results supports a second use of sofosbuvir against yellow fever.

2 May 2016 in bioRxiv
Verified
Preprint
Open access
PDF file
RDRodrigo Delvecchio
Rodrigo Delvecchio
LHLuiza Higa
Luiza Higa
PPPaula Pezzuto
Paula Pezzuto
AVAna Luiza Valadão
Ana Luiza Valadão
PGPatricia Pestana Garcez
Patricia Pestana Garcez
ATAmilcar Tanuri
Amilcar Tanuri
Summary: Zika virus (ZIKV) infection in utero might lead to microcephaly and other congenital defects. In adults, cases of Guillain-Barré syndrome and meningoencephalitis associated with ZIKV infection have been reported, and no specific therapy is available so far. There is urgency for the discovery of antiviral agents capable of inhibiting viral replication and its deleterious effects. Chloroquine is widely administered as an antimalarial drug, anti-inflammatory agent, and it also shows antiviral activity against several viruses. Here we show that chloroquine exhibits antiviral activity against ZIKV in VERO, human brain microvascular endothelial, and neural stem cells. We demonstrated in vitro that chloroquine reduces the number of ZIKV-infected cells, virus production and cell death promoted by ZIKV infection without cytotoxic effects. Our results suggest that chloroquine is a promising candidate for ZIKV clinical trials, since it is already approved for clinical use and can be safely administered to pregnant woman.

1 January 2019 in ASN Neuro
Verified
Journal Article
Open access
PDF file
FCFernanda L. Castro
Fernanda L. Castro
VGVictor E. V. Geddes
Victor E. V. Geddes
FMFábio L. L. Monteiro
Fábio L. L. Monteiro
RGRaphael M. D. T. Gonçalves
Raphael M. D. T. Gonçalves
LCLoraine Campanati
Loraine Campanati
RARenato Aguiar
Renato Aguiar
Zika virus (ZIKV) is an arthropod-borne virus (arbovirus) member of the Flaviviridae family, which has been associated with the development of the congenital Zika syndrome (CZS). RNA viruses, such as flaviviruses, have been reported to exert a profound impact on host microRNAs (miRNAs). Cellular miRNAs modulated by ZIKV may help identify cellular pathways of relevance to pathogenesis. Here, we screened 754 human cellular miRNAs modulated by ZIKV infection (Brazilian PE strain) in a neuroblastoma cell line. Seven miRNAs (miR-99a*, miR-126*, miR-190b, miR-361-3p, miR-522-3p, miR-299-5p, and miR-1267) were downregulated during ZIKV infection, while miR-145 was upregulated. Furthermore, 11 miRNAs were exclusively expressed in ZIKV-infected (miR-148a, miR-342-5p, miR-598, and miR-708-3p) or mock cells (miR-208, miR-329, miR-432-5p, miR-488, miR-518b, miR-520g, and miR-767-5p). Furthermore, in silico analysis indicated that some central nervous system, cellular migration, and adhesion function-related biological processes were overrepresented in the list of target genes of the miRNAs regulated in ZIKV-infected cells, especially for miR-145 and miR-148a. The induction of miR-145 and miR-148a was confirmed in postmortem brain samples from stillborn with severe CZS. Finally, we determined the expression regulation of microcephaly related genes through RNA interference pathway caused by ZIKV directly on neuron cells.

23 October 2021 in iScience
Verified
Journal Article
Open access
LCLuis Eduardo R. Cunha
Luis Eduardo R. Cunha
ASAdilson A. Stolet
Adilson A. Stolet
MSMarcelo A. Strauch
Marcelo A. Strauch
VPVictor A.R. Pereira
Victor A.R. Pereira
CDCarlos H. Dumard
Carlos H. Dumard
JSJerson Silva
Jerson Silva
We used the recombinant trimeric spike (S) glycoprotein in the prefusion conformation to immunize horses for the production of hyperimmune globulins against SARS-CoV-2. Serum antibody titers measured by ELISA were above 1:106, and the neutralizing antibody titer against authentic virus (WT) was 1:14,604 (average PRNT90). Plasma from immunized animals was pepsin digested to remove the Fc portion and purified, yielding an F(ab’)2 preparation with PRNT90 titers 150-fold higher than the neutralizing titers in human convalescent plasma. Challenge studies were carried out in hamsters and showed the in vivo ability of equine F(ab’)2 to reduce viral load in the pulmonary tissues and significant clinical improvement determined by weight gain. The neutralization curve by F(ab’)2 was similar against the WT and P.2 variants, but displaced to higher concentrations by 0.39 log units against the P.1 (Gamma) variant. These results support the possibility of using equine F(ab’)2 preparation for the clinical treatment of COVID patients.